CN113648259A - Toning lotion composition containing skin-firming liposome and preparation method thereof - Google Patents
Toning lotion composition containing skin-firming liposome and preparation method thereof Download PDFInfo
- Publication number
- CN113648259A CN113648259A CN202111126537.9A CN202111126537A CN113648259A CN 113648259 A CN113648259 A CN 113648259A CN 202111126537 A CN202111126537 A CN 202111126537A CN 113648259 A CN113648259 A CN 113648259A
- Authority
- CN
- China
- Prior art keywords
- skin
- composition
- liposome
- tightening
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 70
- 239000002502 liposome Substances 0.000 title claims abstract description 58
- 239000006210 lotion Substances 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 230000000694 effects Effects 0.000 claims abstract description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 41
- 206010020649 Hyperkeratosis Diseases 0.000 claims abstract description 33
- 239000000706 filtrate Substances 0.000 claims abstract description 27
- 229940075599 ascophyllum nodosum extract Drugs 0.000 claims abstract description 19
- 239000002994 raw material Substances 0.000 claims abstract description 15
- JYVXNLLUYHCIIH-UHFFFAOYSA-N (+/-)-mevalonolactone Natural products CC1(O)CCOC(=O)C1 JYVXNLLUYHCIIH-UHFFFAOYSA-N 0.000 claims abstract description 13
- JYVXNLLUYHCIIH-ZCFIWIBFSA-N R-mevalonolactone, (-)- Chemical compound C[C@@]1(O)CCOC(=O)C1 JYVXNLLUYHCIIH-ZCFIWIBFSA-N 0.000 claims abstract description 13
- 229940057061 mevalonolactone Drugs 0.000 claims abstract description 13
- 239000002904 solvent Substances 0.000 claims abstract description 10
- 239000002738 chelating agent Substances 0.000 claims abstract description 8
- 239000003906 humectant Substances 0.000 claims abstract description 8
- 239000002562 thickening agent Substances 0.000 claims abstract description 8
- 241000720991 Illicium Species 0.000 claims abstract description 6
- 239000003755 preservative agent Substances 0.000 claims abstract description 6
- 230000002335 preservative effect Effects 0.000 claims abstract description 6
- 239000008367 deionised water Substances 0.000 claims abstract description 4
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 30
- 238000003756 stirring Methods 0.000 claims description 25
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 24
- 239000012071 phase Substances 0.000 claims description 18
- 230000002500 effect on skin Effects 0.000 claims description 17
- 239000000284 extract Substances 0.000 claims description 15
- 241001534815 Hypsizygus marmoreus Species 0.000 claims description 14
- 239000012074 organic phase Substances 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 14
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 12
- 235000012000 cholesterol Nutrition 0.000 claims description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 239000000787 lecithin Substances 0.000 claims description 12
- 235000010445 lecithin Nutrition 0.000 claims description 12
- 229940067606 lecithin Drugs 0.000 claims description 12
- 150000002596 lactones Chemical class 0.000 claims description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 10
- 229920001577 copolymer Polymers 0.000 claims description 10
- 239000002245 particle Substances 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 9
- 239000000243 solution Substances 0.000 claims description 9
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 8
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims description 8
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 230000036571 hydration Effects 0.000 claims description 6
- 238000006703 hydration reaction Methods 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 6
- 230000010355 oscillation Effects 0.000 claims description 6
- 239000008055 phosphate buffer solution Substances 0.000 claims description 6
- -1 polyethylene Polymers 0.000 claims description 6
- 238000009210 therapy by ultrasound Methods 0.000 claims description 6
- 230000001804 emulsifying effect Effects 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 4
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 4
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 claims description 4
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 claims description 4
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 4
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 claims description 4
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 claims description 4
- 229920002126 Acrylic acid copolymer Polymers 0.000 claims description 4
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 4
- 241000208681 Hamamelis virginiana Species 0.000 claims description 4
- 239000004698 Polyethylene Substances 0.000 claims description 4
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 4
- 229960000458 allantoin Drugs 0.000 claims description 4
- 230000002421 anti-septic effect Effects 0.000 claims description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 4
- 239000000498 cooling water Substances 0.000 claims description 4
- 229920006037 cross link polymer Polymers 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- 238000007599 discharging Methods 0.000 claims description 4
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 235000011187 glycerol Nutrition 0.000 claims description 4
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 4
- YLGYACDQVQQZSW-UHFFFAOYSA-N n,n-dimethylprop-2-enamide Chemical compound CN(C)C(=O)C=C YLGYACDQVQQZSW-UHFFFAOYSA-N 0.000 claims description 4
- 229960005323 phenoxyethanol Drugs 0.000 claims description 4
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims description 4
- 229920000573 polyethylene Polymers 0.000 claims description 4
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims description 4
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims description 4
- 229940113124 polysorbate 60 Drugs 0.000 claims description 4
- 239000001509 sodium citrate Substances 0.000 claims description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 4
- 239000001540 sodium lactate Substances 0.000 claims description 4
- 229940005581 sodium lactate Drugs 0.000 claims description 4
- 235000011088 sodium lactate Nutrition 0.000 claims description 4
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims description 4
- 229940104256 sodium taurate Drugs 0.000 claims description 4
- 229940104261 taurate Drugs 0.000 claims description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 3
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 2
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 241000195633 Dunaliella salina Species 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 2
- 240000007594 Oryza sativa Species 0.000 claims description 2
- 235000007164 Oryza sativa Nutrition 0.000 claims description 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims description 2
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 229960003121 arginine Drugs 0.000 claims description 2
- 229960002685 biotin Drugs 0.000 claims description 2
- 235000020958 biotin Nutrition 0.000 claims description 2
- 239000011616 biotin Substances 0.000 claims description 2
- 229940094978 bis-peg-18 methyl ether dimethyl silane Drugs 0.000 claims description 2
- 238000009835 boiling Methods 0.000 claims description 2
- 229960001948 caffeine Drugs 0.000 claims description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 2
- 229940041514 candida albicans extract Drugs 0.000 claims description 2
- 239000004202 carbamide Substances 0.000 claims description 2
- 229960001631 carbomer Drugs 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- 229960001777 castor oil Drugs 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 230000003750 conditioning effect Effects 0.000 claims description 2
- 229960000735 docosanol Drugs 0.000 claims description 2
- 229940100524 ethylhexylglycerin Drugs 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 2
- 229940051250 hexylene glycol Drugs 0.000 claims description 2
- 235000012907 honey Nutrition 0.000 claims description 2
- 229940089468 hydroxyethylpiperazine ethane sulfonic acid Drugs 0.000 claims description 2
- 229960003646 lysine Drugs 0.000 claims description 2
- AEIJTFQOBWATKX-UHFFFAOYSA-N octane-1,2-diol Chemical compound CCCCCCC(O)CO AEIJTFQOBWATKX-UHFFFAOYSA-N 0.000 claims description 2
- 229960003104 ornithine Drugs 0.000 claims description 2
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 claims description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 2
- 229940068977 polysorbate 20 Drugs 0.000 claims description 2
- 229940078492 ppg-17 Drugs 0.000 claims description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 2
- 229960003415 propylparaben Drugs 0.000 claims description 2
- 235000009566 rice Nutrition 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 229940083466 soybean lecithin Drugs 0.000 claims description 2
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- 239000012138 yeast extract Substances 0.000 claims description 2
- 239000011670 zinc gluconate Substances 0.000 claims description 2
- 235000011478 zinc gluconate Nutrition 0.000 claims description 2
- 229960000306 zinc gluconate Drugs 0.000 claims description 2
- 239000003974 emollient agent Substances 0.000 claims 7
- GHJOIQFPDMIKHT-UHFFFAOYSA-N propane-1,2,3-triol;prop-2-enoic acid Chemical compound OC(=O)C=C.OCC(O)CO GHJOIQFPDMIKHT-UHFFFAOYSA-N 0.000 claims 1
- 210000003491 skin Anatomy 0.000 abstract description 121
- 230000037394 skin elasticity Effects 0.000 abstract description 15
- 239000002537 cosmetic Substances 0.000 abstract description 13
- 210000004207 dermis Anatomy 0.000 abstract description 11
- 210000002615 epidermis Anatomy 0.000 abstract description 6
- 230000002195 synergetic effect Effects 0.000 abstract description 6
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 230000037303 wrinkles Effects 0.000 description 23
- 238000012360 testing method Methods 0.000 description 22
- 210000001061 forehead Anatomy 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 10
- 239000001963 growth medium Substances 0.000 description 10
- 230000037393 skin firmness Effects 0.000 description 10
- 102000008186 Collagen Human genes 0.000 description 9
- 108010035532 Collagen Proteins 0.000 description 9
- 229920001436 collagen Polymers 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 239000000686 essence Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 206010040914 Skin reaction Diseases 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000001815 facial effect Effects 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000035483 skin reaction Effects 0.000 description 4
- 231100000430 skin reaction Toxicity 0.000 description 4
- 238000004114 suspension culture Methods 0.000 description 4
- OWPUOLBODXJOKH-UHFFFAOYSA-N 2,3-dihydroxypropyl prop-2-enoate Chemical compound OCC(O)COC(=O)C=C OWPUOLBODXJOKH-UHFFFAOYSA-N 0.000 description 3
- 241000512259 Ascophyllum nodosum Species 0.000 description 3
- 241000125183 Crithmum maritimum Species 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 206010050637 Skin tightness Diseases 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 230000036548 skin texture Effects 0.000 description 3
- 238000002791 soaking Methods 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000199919 Phaeophyceae Species 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000005282 brightening Methods 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- CXEGAUYXQAKHKJ-NSBHKLITSA-N emamectin B1a Chemical compound C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](NC)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 CXEGAUYXQAKHKJ-NSBHKLITSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 238000007665 sagging Methods 0.000 description 2
- 239000013535 sea water Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 239000012879 subculture medium Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 description 1
- KJTLQQUUPVSXIM-ZCFIWIBFSA-N (R)-mevalonic acid Chemical compound OCC[C@](O)(C)CC(O)=O KJTLQQUUPVSXIM-ZCFIWIBFSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000512260 Ascophyllum Species 0.000 description 1
- 229930192334 Auxin Natural products 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- KJTLQQUUPVSXIM-UHFFFAOYSA-N DL-mevalonic acid Natural products OCCC(O)(C)CC(O)=O KJTLQQUUPVSXIM-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229930191978 Gibberellin Natural products 0.000 description 1
- 241001537183 Hypecoum Species 0.000 description 1
- 241000198061 Illicium henryi Species 0.000 description 1
- 239000005717 Laminarin Substances 0.000 description 1
- 229920001543 Laminarin Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 240000002834 Paulownia tomentosa Species 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 241000235004 Saccharomycopsis fibuligera Species 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000002363 auxin Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 239000004062 cytokinin Substances 0.000 description 1
- UQHKFADEQIVWID-UHFFFAOYSA-N cytokinin Natural products C1=NC=2C(NCC=C(CO)C)=NC=NC=2N1C1CC(O)C(CO)O1 UQHKFADEQIVWID-UHFFFAOYSA-N 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- IXORZMNAPKEEDV-UHFFFAOYSA-N gibberellic acid GA3 Natural products OC(=O)C1C2(C3)CC(=C)C3(O)CCC2C2(C=CC3O)C1C3(C)C(=O)O2 IXORZMNAPKEEDV-UHFFFAOYSA-N 0.000 description 1
- 239000003448 gibberellin Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 230000005808 skin problem Effects 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- MSXHSNHNTORCAW-MPGIDXPLSA-M sodium;(3s,4s,5s,6r)-3,4,5,6-tetrahydroxyoxane-2-carboxylate Chemical compound [Na+].O[C@@H]1OC(C([O-])=O)[C@@H](O)[C@H](O)[C@@H]1O MSXHSNHNTORCAW-MPGIDXPLSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
- A61K8/9711—Phaeophycota or Phaeophyta [brown algae], e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
- A61K8/988—Honey; Royal jelly, Propolis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Dermatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses a toning lotion composition containing liposome with skin tightening effect and a preparation method thereof. The toning lotion composition comprises the following components in percentage by weight: 0.05-35% of skin-tightening efficacy composition liposome, 5-30% of humectant, 0-30% of skin conditioner, 0-10% of thickening agent, 0.01-2% of chelating agent, 0.01-1% of solubilizer, a proper amount of pH regulator, a proper amount of preservative, 0.01-1.0% of daily essence and the balance of deionized water. Wherein the effective composition comprises Ascophyllum nodosum extract, mevalonolactone and Criste anisetree callus culture filtrate. The invention prepares the three functional components into the functional composition liposome which is added into cosmetics, can promote transdermal absorption, effectively acts on two skin layers of skin epidermis and dermis, enhances the skin elasticity and tightens the skin. The skin firming lotion disclosed by the invention achieves a safe and effective skin firming effect by scientifically combining the raw materials and utilizing the synergistic effect among the functional components, so that the skin is full of elasticity, and the young skin state is kept.
Description
Technical Field
The invention relates to a skin care product and a preparation method thereof, belongs to the technical field of daily chemicals, and particularly relates to a toning lotion composition containing skin-tightening liposome and a preparation method thereof.
Background
In daily life, skin sagging is a very disturbing skin problem that is difficult to cover simply by means of make-up or the like. Generally, as a person ages, the loss of collagen and lipids causes the skin to age and relax. In addition, the microbial balance of the skin is disrupted, the skin is exposed to a polluted environment, and factors such as sunlight irradiation and gravity effect also cause aging and relaxation of the skin, and sagging of the skin occurs. Collagen produced by fibroblasts in the dermis is a main component of the dermis and has important functions of maintaining the structure of the skin and endowing the skin with tightness and elasticity, and the content and distribution of the collagen determine whether the skin is young or not.
In the prior art, an anti-aging product mixed with various components such as hydrolyzed collagen, hyaluronic acid, polypeptide, retinol and derivatives thereof is provided, but the anti-aging product is difficult to be absorbed through skin and acts on the dermis of skin to supplement collagen, so that the anti-aging product has an effective tightening effect.
Therefore, how to develop a safe and effective cosmetic with skin-tightening effect becomes a difficult point to be solved by the technicians in the cosmetic industry at present.
Disclosure of Invention
The present invention has an object to provide a toning lotion composition containing liposomes having skin firming effects, which can effectively protect the skin from damage caused by ultraviolet rays, help prevent photoaging of the epidermis and dermis, improve or restore the function of the dermis, stimulate the synthesis of fibers (such as collagen, elastin, and proteoglycan) in the extracellular matrix, and keep the skin moisturized, elastic and firm.
The invention also aims to provide a preparation method of the toning lotion composition with the skin firming effect liposome.
In order to achieve the purpose, the invention adopts the following technical scheme:
the toning lotion composition containing the skin-firming effect liposome comprises the following raw material components in percentage by weight of the total weight of the composition:
0.05-35% firming skin effect composition liposomes, said firming skin effect composition liposomes comprising: ascophyllum nodosum extract 0.01-30%, methyl-tile-acid lactone 0.01-30% and hypecol callus culture filtrate 0.01-30%;
5-30% of humectant;
0-30% of a skin conditioning agent;
0-10% of a thickening agent;
0.3-5.0% of preservative;
0.01-2% of a chelating agent;
0.01-1% of a solubilizer;
0.01-1.0% of daily essence;
proper amount of pH regulator and deionized water.
Further, the cosmetic water composition containing the skin-tightening efficacy liposome comprises the following components in percentage by weight of the total weight of the composition:
0.2-25% firming skin efficacy composition liposomes comprising: 0.05-20% of Ascophyllum nodosum extract, 0.05-20% of methyl-tile lactone and 0.05-20% of hypsizygus marmoreus callus culture filtrate;
further, the firming skin effect composition liposome comprises the following raw material components:
0.05-10% of Ascophyllum nodosum extract, 0.05-10% of methyl-tile lactone and 0.05-10% of hypsizygus marmoreus callus culture filtrate.
Further, the firming skin effect composition liposome comprises the following raw material components:
0.05-3% of Ascophyllum nodosum extract, 0.05-3% of methyl-tile lactone and 0.05-3% of hypsizygus marmoreus callus culture filtrate.
Further, the cosmetic water composition containing the skin-tightening efficacy liposome comprises the following components in percentage by weight of the total weight of the composition:
0.25-10% firming skin efficacy composition liposomes comprising: 0.05-0.5% of Ascophyllum nodosum extract, 0.05-0.5% of methyl-tile lactone and 0.05-0.5% of hypsizygus marmoreus callus culture filtrate;
further, the humectant is selected from one or more of glycerin, propylene glycol, 1, 3-propylene glycol, glyceryl acrylate/acrylic acid copolymer, glyceryl polyether-26, hexylene glycol, 1, 2-pentanediol, caprylyl glycol, ethylhexyl glycerin, polyethylene glycol-32, urea, allantoin, PEG/PPG-17/6 copolymer, PPG-28-Butaneth-35, bis-PEG-18 methyl ether dimethylsilane, sorbitol, and combinations thereof;
the skin conditioner is selected from one or more of honey extract, arginine, lysine, ornithine, sodium lactate, nicotinamide, yeast extract, Hamamelis virginiana extract, rice chaff extract, ammonium glycyrrhizinate, zinc gluconate, caffeine, and biotin;
the thickening agent is selected from one or a combination of acryloyl dimethyl ammonium taurate/VP copolymer, acryloyl dimethyl ammonium taurate/behenyl alcohol polyether-25 methacrylate cross-linked polymer, sodium polyacrylate, acrylic acid (ester) copolymer sodium, polyacrylate-13, hydroxyethyl acrylate/acryloyl dimethyl sodium taurate copolymer, xanthan gum, hydroxyethyl acrylate/acryloyl dimethyl sodium taurate copolymer, carbomer, acrylic acid (ester)/C10-30 alkanol acrylate cross-linked polymer;
the preservative is selected from one or more of methyl hydroxybenzoate, propyl hydroxybenzoate and phenoxyethanol;
the chelating agent is one or more selected from EDTA-disodium, EDTA-tetrasodium and the composition thereof;
the solubilizer is one or more selected from PEG-60 hydrogenated castor oil, polysorbate-20 and polysorbate-60.
The pH regulator is selected from one or more of citric acid, sodium citrate, hydroxyethyl piperazine ethane sulfonic acid and a composition thereof.
The preparation process of the composition liposome with the skin tightening effect comprises the following steps:
1) dissolving lecithin and cholesterol in diethyl ether, and shaking to dissolve until the solution is transparent to obtain an organic phase;
2) removing the ether from the organic phase in the step 1) at constant temperature of 40 ℃ under reduced pressure until a layer of transparent film is formed on the inner side of the bottle wall, and drying for 10min to obtain a dried substance;
3) dissolving Ascophyllum Nodosum extract, mevalonolactone and hypecol callus culture filtrate in phosphate buffer solution with pH of 6.0 to obtain water phase effective components;
4) adding the water phase functional components obtained in the step 3) into the dried substance obtained in the step 2), and performing normal-pressure rotation oscillation hydration and demoulding at the temperature of 35 ℃;
5) and (3) carrying out ultrasonic treatment for 5-20min after complete membrane removal, and filtering to obtain the compact skin effect liposome with uniform particle size.
Preferably, the lecithin is soybean lecithin, and the mass ratio of the lecithin to cholesterol is (2-5): 1;
the mass ratio of the dunaliella salina extract, the mevalonolactone and the hypsizygus marmoreus callus culture filtrate to the lecithin is 1 (1-3): 0.5-1.5): 20-30;
the volume ratio of the water phase to the organic phase is 1 (2-5).
Preferably, the prepared liposome has a particle size of 0.1-0.5 μm.
In addition, the invention also discloses a preparation method of the toning lotion composition with the skin tightening effect liposome, which comprises the following process steps:
1) adding water, chelating agent, humectant, thickener, part of antiseptic, and pH regulator into water phase pot, stirring and heating to 80-85 deg.C, keeping the temperature and stirring for 20-25 min;
2) boiling cooling water, stirring, cooling to 40-45 deg.C, adding the composition liposome with skin tightening effect, skin conditioner, solubilizer, essence and other antiseptic, adding into emulsifying pot, and stirring for 15-20 min;
3) and continuously stirring and cooling until the temperature is lower than 38 ℃, stopping stirring, and discharging after the detection is qualified.
Further, the cosmetic water composition containing the skin-firming effect liposome is prepared by dispersing or suspending the cosmetic water composition in a solvent, or is prepared by emulsifying particles or is prepared by coating a polymer.
Specifically, the cosmetic containing the liposome with the skin tightening effect is a skin care product, in particular emulsion, essence, cream, eye cream, body lotion, gel and sun block lotion.
By means of the technical scheme, the invention has the following advantages and beneficial technical effects:
1) the invention contains a variety of effective components with skin tightening effect, such as the extract of the Ascophyllum nodosum, the mevalonolactone and the hypsizygus marmoreus callus culture filtrate, and can tighten skin through the synergistic effect of a plurality of ways; the invention selects the extract of the Ascophyllum nodosum, the mevalonolactone and the hypsizygus marmoreus callus culture filtrate, prepares the composite of the carriers acceptable for cosmetics by a liposome preparation technology, finds the most preferable composition proportion by the preferable combination and the efficacy test, and plays the best effect of tightening the skin;
2) the toning lotion disclosed by the invention contains the liposome with the skin tightening effect, and all the components are mutually synergistic, so that the safe and effective skin tightening effect is achieved. The liposome of the efficacy composition prepared from the three efficacy components can be added into cosmetics to promote transdermal absorption, effectively act on two skin layers of skin epidermis and dermis, enhance skin elasticity and tighten skin.
3) The innovative skin-tightening effect lotion has the advantages that the effect components exist in the form of the liposome, can permeate into the deep layer of the skin, directly and effectively supplement nutrition to the skin, stimulate the regeneration of epidermis and the synthesis of collagen, promote the self-generation of cholesterol in the skin, effectively maintain the elasticity of the skin, capture free radicals, repair the damaged skin and tighten the skin.
4) The skin firming lotion disclosed by the invention achieves a safe and effective skin firming effect finally by scientifically combining the raw materials and utilizing the synergistic effect among the functional components, so that the skin is full of elasticity, and the young skin state is kept. The various functional components have the effects of promoting cell renewal of epidermis and dermis, controlling inflammation, stimulating the synthesis of fibers in extracellular matrix, preventing ultraviolet injury, etc.
Drawings
FIG. 1 is the skin wrinkle Ra value after use of example 1;
FIG. 2 is the F4 value for skin firmness after use of example 1;
FIG. 3 is the R2 values for skin elasticity after use of example 1;
FIG. 4 is a clinical evaluation of external canthus wrinkle score by a dermatologist after using example 1;
FIG. 5 is the smoothness score of the skin clinically evaluated by the dermatologist after use of example 1;
FIG. 6 is a dermatologist clinical assessment of the full-face fine-grain score after using example 1;
FIG. 7 is a clinical assessment of skin firmness scores by a dermatologist after using example 1.
Detailed Description
The invention discloses a toning lotion composition of firming skin effect liposome containing multiple firming skin effect components and a preparation method thereof. The skin tightening toning lotion comprises the following raw material components:
0.3-35% of lipidosome with the effect of tightening the skin, 5-30% of humectant, 0-30% of skin conditioner, 0-10% of thickening agent, 0.01-2% of chelating agent, 0.01-1% of solubilizer, a proper amount of pH regulator, a proper amount of preservative, 0.01-1.0% of essence for daily use and the balance of deionized water.
The skin tightening functional component is prepared by mixing a paulownia extract, a methyl-tile-shaped lactone and a hypsizygus marmoreus callus culture filtrate.
(ii) Ascophyllum nodosum extract
Ascophyllum, Phaeophyceae, grows primarily in the North Atlantic Europe and along the Canadian coast. The appearance is slender, the branches are dense and irregular, the edges of the branches are in a shape of blunt saw teeth, the edges of the branches have organs like roots, stems, leaves and the like, the branches are in a brown green color, and a nutrition bubble is arranged in the middle of the branches. The sea water has tenacious vitality, grows on rocks beside the sea or on the sea bottom, has strong enrichment and absorption capacity, can enrich the nutrition in the sea water, and metabolizes and synthesizes dozens of bioactive substances such as seaweed polysaccharide, mannitol, phenols, alginate, brown algae polyphenol, laminarin, fucoidin, cytokinin, gibberellin and the like.
The Ascophyllum nodosum extract has various effects on skin care, and can help to accelerate cell renewal of epidermis and dermis layers and stimulate skin regeneration; can resist the damage of UVB radiation to the skin and promote cell metabolism; preventing the leather fiber from deteriorating and reducing the generation of wrinkles; regulating cytokine, controlling inflammation, and promoting skin repair.
The preparation method comprises the following steps:
1) pretreatment of raw materials: taking fresh soaked-leaf algae as a raw material, removing impurities such as straw sticks, silt and the like attached to the algae leaves, soaking in a 75% ethanol solution for 15-30 min, and airing for later use;
2) grinding, crushing and extracting: adding a small amount of liquid nitrogen into the raw materials in the step 1), grinding, crushing by using a tissue triturator, and extracting for 12 hours at the temperature of 30 ℃ by using 90% ethanol as an extraction solvent;
3) filtering and distilling under reduced pressure: quickly filtering the extract obtained in the step 2) by using a Buchner funnel, and distilling the filtrate under reduced pressure to remove ethanol so as to obtain the extract of the Ascophyllum nodosum.
② methyl tile acid lactone
The mevalonolactone is extracted from "Saccharomycopsis fibuligera". When it is put into water, that is, into a formula, it is immediately turned into "mevalonic acid", which is a substance that the human body itself contains. Healthy human skin requires 3 kinds of intercellular lipids, and stable connection of the intercellular lipids is essential for skin health. Among the three intercellular lipids, "cholesterol" is reduced with the age, and the emamectin benzoate is an indispensable intermediate for the human body to synthesize cholesterol, supplements the cholesterol which is needed by the emamectin benzoate and can well stimulate the skin to synthesize by itself, solves various problems of the skin from a deeper layer, effectively maintains the skin thickness and keeps the skin elasticity.
③ Illicium henryi callus culture filtrate
The sea fennel callus culture filtrate is derived from plant stem cells extracted from the root of the sea fennel callus culture, and the stem cells contain phenolic acid, chlorogenic acid, flavonoid and the like to be on the dermal layer, and can stimulate the synthesis of fibers in extracellular matrix, such as collagen, elastin and proteoglycan.
At the same time, it also helps to balance the production of keratinocytes and epidermal regeneration in terms of cell size, both skin layers can be more densified and globally balanced. The hypsizygus marmoreus callus culture filtrate is beneficial to compacting dermis and tightening skin. Is helpful for improving or restoring dermal function and enhancing skin resistance.
The preparation method comprises the following steps:
1) cleaning fresh sea fennel roots and stems with clear water, airing, soaking for 30s with 75% ethanol solution, soaking for 60 min with 25.0g/L sodium hypochlorite disinfectant, and cleaning with sterile water to remove disinfectant residues;
2) cutting the sterile explant obtained in the step 1) into 1cm long strips, inoculating the long strips into a callus induction culture medium for culture, placing the culture medium in a culture room with the temperature of 22-26 ℃ and the illumination intensity of 1800-2000 LX, illuminating for 12h/d, and culturing for 20-25d to induce callus;
3) selecting yellow green loose callus, and pulverizing into 0.5cm2Inoculating the small blocks into a subculture medium for subculture, and continuously subculturing for 4 times by taking 20d as a period to obtain callus which grows vigorously, has small particles and is loose, wherein the subculture conditions are the same as the induction culture conditions in the step 2);
4) crushing the callus in the step 3), adding 60-100mg/kg of cellulase for treating for 3-5 hours, filtering by a 100-micron microporous filter, centrifuging at low speed, removing supernatant, collecting seed cells, inoculating the seed cells into a cell suspension culture medium, wherein the inoculation amount is 50g/L, the rotating speed is 100r/min, the temperature is 25 ℃, performing shaking culture, and stopping the culture when the cell count is more than 20000/mL;
5) inoculating the cultured cells in step 4) into MS culture medium, adding auxin IAA 5-10mg/L and pectase 50-100mg/L, performing suspension culture in bioreactor at stirring rate of 100r/min and pH of 5-6 at 0.03m3Introducing sterile oxygen gas/s, culturing in dark for 20-30 days, and stopping culturing when the cell count is above 45000/mL;
6) centrifuging and collecting to obtain hypecoum vulgare callus culture filtrate.
Wherein, the callus induction culture medium and the subculture medium in the steps 2) and 3) are solid culture media, and the formulas are respectively as follows: MS +2.5 mg/L2, 4-D +2.5 mg/L6-BAA +5g/L vitamin C +30g/L sucrose +7g/L agar, pH 5.5 and MS +2.5 mg/L2, 4-D +3.0mg/L ZT, pH 5.8. The cell suspension culture medium in the step 4) is a liquid culture medium, and the formula of the cell suspension culture medium is as follows: MS culture medium +1.5 mg/L2, 4-D +0.5 mg/L6-BA +200mg/L hydrolyzed casein +40g/L sucrose, and pH value is 5.8.
The toning lotion composition of the skin tightening effect liposome is composed of the ascophyllum nodosum extract, the mevalonolactone and the hypsizygus marmoreus callus culture filtrate, and nourishes the skin through the composition to form a skin barrier, resist the damage of environmental pollutants to the skin, enhance the toughness of the dermis, prevent and repair the skin photodamage, promote the synthesis of collagen and lipid, maintain the skin elasticity and have the skin tightening effect.
Normally, the skin can only absorb some electrolytes, small molecular substances and fat-soluble substances, wherein the stratum corneum is the most important path for skin absorption. The skin-tightening efficacy composition liposome can easily penetrate through the stratum corneum, and water-soluble macromolecule efficacy ingredients are carried to the deep layer of the skin, so that the skin-tightening effect is better exerted.
The present invention is illustrated by the following examples, which are provided for the purpose of further illustration only and are not intended to limit the scope of the present invention. Other insubstantial modifications and adaptations of the present invention can be made without departing from the scope of the present invention.
Unless otherwise specified, the following percentages (%) are mass percentages. All the raw material components used in the invention are commercial products.
Examples 1 to 4
A cosmetic water composition containing liposome with skin tightening effect is provided, and the raw material components of examples 1-4 have the proportion contents shown in the following table 1.
Table 1 examples 1 to 4 raw material composition ratios (unit: mass%)
The method for preparing the toning lotion composition with the skin tightening effect of the embodiments 1 to 4 of the invention can be expressed as follows:
1) adding water, allantoin, EDTA-disodium, citric acid, sodium citrate, glyceryl polyether-26, glycerol, glyceryl acrylate/acrylic acid copolymer, 1, 3-propylene glycol, polyethylene glycol-32, sodium polyacrylate and methyl hydroxybenzoate into a water phase pot, stirring and heating to 80-85 deg.C, maintaining the temperature and stirring for 20-25 min;
2) adding cooling water, stirring, cooling to 40-45 deg.C, adding tightening skin effect composition liposome, sodium lactate, Hamamelis virginiana extract, polysorbate-60, essence, and phenoxyethanol, adding into emulsifying pot, and stirring for 15-20 min;
3) and continuously stirring and cooling until the temperature is lower than 38 ℃, stopping stirring, and discharging after the detection is qualified.
Specifically, the preparation method of the liposome of the firming skin effect composition of example 1 comprises the following steps:
1) dissolving 1680mg of lecithin and 480mg of cholesterol in 40mL of diethyl ether, and shaking for dissolution until the solution is transparent to obtain an organic phase;
2) removing the ether from the organic phase in the step 1) at constant temperature of 40 ℃ under reduced pressure until a layer of transparent film is formed on the inner side of the bottle wall, and drying for 10 min;
3) dissolving 60mg of Ascophyllum nodosum extract, 120mg of mevalonolactone and 60mg of Criste anisetree callus culture filtrate in 15mL of phosphate buffer solution with pH of 6.0 to obtain water phase effective components;
4) adding the water phase functional components obtained in the step 3) into the dried substance obtained in the step 2), and performing normal-pressure rotation oscillation hydration and demoulding at the temperature of 35 ℃;
5) and (3) carrying out ultrasonic treatment for 5-20min after complete membrane removal, and filtering to obtain the compact skin effect liposome with uniform particle size.
Specifically, the preparation method of the skin tightening efficacy composition liposome of the embodiment 2 comprises the following process steps:
1) dissolving 1260mg of lecithin and 360mg of cholesterol in 30mL of diethyl ether, and shaking for dissolving until the solution is transparent to obtain an organic phase;
2) removing the ether from the organic phase in the step 1) at constant temperature of 40 ℃ under reduced pressure until a layer of transparent film is formed on the inner side of the bottle wall, and drying for 10 min;
3) dissolving 45mg of Ascophyllum nodosum extract, 90mg of mevalonolactone and 45mg of Criste anisetree callus culture filtrate in 10mL of phosphate buffer solution with pH of 6.0 to obtain water phase effective components;
4) adding the water phase functional components obtained in the step 3) into the dried substance obtained in the step 2), and performing normal-pressure rotation oscillation hydration and demoulding at the temperature of 35 ℃;
5) and (3) carrying out ultrasonic treatment for 5-20min after complete membrane removal, and filtering to obtain the compact skin effect liposome with uniform particle size.
Specifically, the preparation method of the skin tightening efficacy composition liposome of the embodiment 3 comprises the following process steps:
1) dissolving 840mg of lecithin and 240mg of cholesterol in 25mL of diethyl ether, shaking and dissolving until the solution is transparent, and obtaining an organic phase;
2) removing the ether from the organic phase in the step 1) at constant temperature of 40 ℃ under reduced pressure until a layer of transparent film is formed on the inner side of the bottle wall, and drying for 10 min;
3) dissolving 30mg of Ascophyllum nodosum extract, 60mg of mevalonolactone and 30mg of Criste anisetree callus culture filtrate in 8mL of phosphate buffer solution with pH of 6.0 to obtain water phase effective components;
4) adding the water phase functional components obtained in the step 3) into the dried substance obtained in the step 2), and performing normal-pressure rotation oscillation hydration and demoulding at the temperature of 35 ℃;
5) and (3) carrying out ultrasonic treatment for 5-20min after complete membrane removal, and filtering to obtain the compact skin effect liposome with uniform particle size.
Specifically, the preparation method of the liposome of the composition for tightening skin of example 4 comprises the following steps:
1) dissolving 420mg of lecithin and 120mg of cholesterol in 20mL of diethyl ether, and shaking for dissolving until the solution is transparent to obtain an organic phase;
2) removing the ether from the organic phase in the step 1) at constant temperature of 40 ℃ under reduced pressure until a layer of transparent film is formed on the inner side of the bottle wall, and drying for 10 min;
3) dissolving 15mg of Ascophyllum nodosum extract, 30mg of mevalonolactone and 15mg of Criste anisetree callus culture filtrate in 6mL of phosphate buffer solution with pH of 6.0 to obtain water phase effective components;
4) adding the water phase functional components obtained in the step 3) into the dried substance obtained in the step 2), and performing normal-pressure rotation oscillation hydration and demoulding at the temperature of 35 ℃;
5) and (3) carrying out ultrasonic treatment for 5-20min after complete membrane removal, and filtering to obtain the compact skin effect liposome with uniform particle size.
Test example for Effect verification
Wrinkle removal Effect test 1
1. The tester: 31 healthy persons (25-55 years old), female: fine lines and dry lines exist on the forehead and the cheek, the facial skin is lack of elasticity, and the face is not obviously reddened, damaged, scarred and the like; the example 1 formulation was tried.
2. Testing parts: the entire face (including the periocular region).
3. Testing an instrument: primos.
4. Testing indexes are as follows: a decrease in the analytical value Ra indicates an improvement in skin wrinkles.
5. The test results are shown in fig. 1 and table 2 below:
TABLE 2 skin wrinkle Ra value after use of example 1
Skin wrinkle Ra value | Before use | After 7 days of use | After 14 days of use | After 28 days of use |
Forehead head | 26.02 | 24.68 | 24.39 | 24.05 |
Cheek | 19.42 | 19.01 | 18.83 | 18.26 |
As can be seen from the results of fig. 1 and table 2, compared to before using the sample: after 7 days of sample use, the forehead skin wrinkle Ra value was significantly reduced by 5.15%, and the cheek skin wrinkle Ra value was significantly reduced by 2.11%; after 14 days of sample use, the forehead skin wrinkle Ra value was significantly reduced by 6.26%, and the cheek skin wrinkle Ra value was significantly reduced by 3.04%; after 28 days using the sample, there was no significant reduction in forehead skin wrinkle Ra value by 7.57%, and a significant reduction in cheek skin wrinkle Ra value by 5.97%.
The skin wrinkle Ra value was significantly reduced after use of example 1, indicating that the firming lotion of the present invention has a relatively significant wrinkle removal effect.
Skin tightening effect test 2
1. The tester: 31 healthy persons (25-55 years old), female: fine lines and dry lines exist on the forehead and the cheek, the facial skin is lack of elasticity, and the face is not obviously reddened, damaged, scarred and the like; the example 1 formulation was tried.
2. Testing parts: the entire face (including the periocular region).
4. testing indexes are as follows: the reduced F4 value for skin firmness indicates that the skin is firmer.
5. The test results are shown in fig. 2 and table 3.
Table 3 skin tightening F4 values after use of example 1
Skin firming F4 | Before use | After 7 days of use | After 14 days of use | After 28 days of use |
Forehead head | 5.35 | 5.28 | 5.12 | 5.06 |
Cheek | 5.15 | 5.03 | 4.95 | 4.81 |
As shown in fig. 2 and table 3, compared to before using the sample: after 7 days of sample application, the forehead skin tightening F4 value was significantly reduced by 1.31%, and the cheek skin tightening F4 value was significantly reduced by 2.33%; 14 days after application of the sample, the forehead skin firmness F4 value was significantly reduced by 4.30%, and the cheek skin firmness F4 value was significantly reduced by 3.88%; after 28 days of use of the sample, there was a significant reduction of 5.42% in the forehead skin firmness F4 value and 6.60% in the cheek skin firmness F4 value.
The above data show that the F4 value for forehead and cheek skin tightening is significantly reduced after example 1 is used, indicating that the tightening efficacy lotion of the present invention has a relatively significant skin tightening effect.
Skin elasticity effect test 3
1. The tester: 30 healthy persons (25-55 years old), female: fine lines and dry lines exist on the forehead and the cheek, the facial skin is lack of elasticity, and the face is not obviously reddened, damaged, scarred and the like; the example 1 formulation was tried.
2. Testing parts: the entire face (including the periocular region).
4. testing indexes are as follows: the measurement increases and closer to 1, indicating better skin elasticity.
5. The test results are shown in fig. 3 and table 4 below:
table 4 skin elasticity R2 values after use of example 1
The results in fig. 3 and table 4 show that, compared to before the use of the sample: after 7 days of using the sample, the forehead skin elasticity R2 value has no significant increase of 1.69%, and the cheek skin elasticity R2 value has a significant increase of 3.70%; after 14 days of sample application, the forehead skin elasticity R2 value was significantly increased by 6.78%, and the cheek skin elasticity R2 value was significantly increased by 9.26%; after 28 days of sample use, there was a significant 10.17% increase in the forehead skin elasticity R2 value and a significant 14.81% increase in the cheek skin elasticity R2 value.
The above results demonstrate that the lotion of the present invention can significantly increase skin elasticity.
Dermatologist clinical assessment 4
1. Evaluation subject: 33 healthy persons (25-55 years old), female: fine lines and dry lines exist on the forehead and the cheek, the facial skin is lack of elasticity, and the face is not obviously reddened, damaged, scarred and the like; the example 1 formulation was tried.
2. Evaluation site: the entire face (including the periocular region).
3. Evaluation indexes are as follows: wrinkles, fine texture, fine lines on the whole face, firmness of the skin.
4. Grading standard: wrinkling: score 0 indicates no wrinkles, score 9 indicates very deep wrinkles; smoothness of skin: 0 score indicates very rough skin, and 9 score indicates very fine skin; fine lines of the whole face: score 0 indicates many visible lines, score 9 indicates that almost no lines were observed; firmness of the skin: a score of 0 indicates that the skin is not tight (slack skin) and is easily deformed by stretching but not easily returned to its original state, and a score of 9 indicates that the skin is very tight, has significant resistance to pulling or pressure, and is easily returned to its original state.
5. And (4) evaluation results: as shown in fig. 4-7 and table 5.
TABLE 5 clinical assessment score for dermatologist
Mean clinical score | Before use | After 14 days of use | After 28 days of use |
External canthus wrinkle | 2.85 | 2.43 | 2.01 |
Fine and smooth skin texture | 4.77 | 5.39 | 6.32 |
Fine lines of whole face | 4.79 | 5.19 | 5.90 |
Firmness of skin | 4.45 | 5.00 | 5.58 |
Compared to before using the sample: after the sample is used for 14 days, the clinical score mean of external canthus wrinkles is reduced by 14.74%, the fine clinical score mean of skin texture is increased by 12.84%, the clinical score mean of full-face fine lines is increased by 8.42%, and the firmness clinical score mean of skin is increased by 12.32%; after the sample is used for 28 days, the clinical score mean of external canthus wrinkles is reduced by 29.48 percent, the fine clinical score mean of skin texture is increased by 32.43 percent, the clinical score mean of full-face fine lines is increased by 23.23 percent, and the tightening clinical score mean of skin is increased by 25.36 percent.
Clinical evaluation results of dermatologists show that the astringent with the tightening effect has remarkable effects on four aspects of reducing external canthus wrinkles, improving skin fineness, smoothing whole face wrinkles and improving skin tightness.
Safety test 5
1. The number of tested persons: 30 healthy people, 13 men and 17 women; the age range is 20-45 years.
2. The test method comprises the following steps: the selection area is not more than 50mm2In a suitable patch tester having a depth of about 1mm, about 0.020 to 0.025mL (g) of the test substance of example 1 was added to the patch tester by the closed patch test method. The patch tester is applied to the curved side of the forearm of the subject, the subject is removed 24 hours later, the skin reaction is observed 0.5 hour, 24 hours and 48 hours after the removal, and the result is recorded according to the skin reaction grading standard in the technical Specification for cosmetic safety 2015.
3. The evaluation criteria are as follows in table 6:
TABLE 6 grading Standard of adverse skin reactions
The results show that: the result of the human skin patch experiment shows that the score grades of 0.5h, 24h and 48h of 3 observation time points after 30 subjects remove the patch are all 0, namely 0 of 30 subjects have positive reaction, and the subject does not cause adverse skin reaction to the subjects in the batch according to the regulation in technical Specification for cosmetic safety (2015 edition).
Synergistic test example 6
A toning lotion composition with skin tightening effect comprises the raw material components of comparative examples 1-7 according to the proportion, and is shown in the following table 7.
Comparative examples 1 to 7
TABLE 7 COMPARATIVE EXAMPLES 1 to 7 raw material composition ratio (% by mass)
The manufacturing process of the toning lotion with skin tightening effect of comparative examples 1 to 7 of the present invention can be expressed as follows:
1) adding water, allantoin, EDTA-disodium, citric acid, sodium citrate, glyceryl polyether-26, glycerol, glyceryl acrylate/acrylic acid copolymer, 1, 3-propylene glycol, polyethylene glycol-32, sodium polyacrylate and methyl hydroxybenzoate into a water phase pot, stirring and heating to 80-85 deg.C, maintaining the temperature and stirring for 20-25 min;
2) adding cooling water, stirring, cooling to 40-45 deg.C, adding tightening skin effective component, sodium lactate, Hamamelis virginiana extract, polysorbate-60, essence, and phenoxyethanol, adding into emulsifying pot, and stirring for 15-20 min;
3) and continuously stirring and cooling until the temperature is lower than 38 ℃, stopping stirring, and discharging after the detection is qualified.
The skin firmness test was performed on the face before and after using example 1 and comparative examples 1 to 7, and the test results are shown in tables 8 to 9.
Table 8 forehead skin firmness F4 values before and after use in example 1 and comparative examples 1-7
Table 9 example 1 and comparative examples 1-7 cheek skin tightening F4 values before and after use
Use ofMPA580 tests the skin tightness F4 value, with a decrease in F4 value indicating a more tight skin. It can be seen from the data in tables 11-12 that the rate of reduction of the forehead skin firmness F4 values after use of example 1 and comparative examples 1-7 is ranked by magnitude: example 1>Comparative example 1>4>3>2>6>5>7; the cheek skin tightness F4 values were ranked by size as: example 1>Comparative example 1>4>2>3>5>6>7。
In conclusion, the compound with the effects of improving skin color and brightening has the effects of remarkably improving skin color and brightening through the synergistic effect of the components, and the effect of improving skin color is more obvious than that of the combination of two or three components.
The above description is only a preferred embodiment of the present invention, and is not intended to limit the present invention in any way, so that any simple modification, equivalent change and modification made to the above embodiment according to the technical spirit of the present invention are within the scope of the technical solution of the present invention.
Claims (9)
1. A toning lotion composition containing a skin-firming effect liposome, which is characterized in that: the composition comprises the following raw material components in percentage by weight:
0.05-35.0% of a firming skin efficacy composition liposome comprising: 0.01-30% of Ascophyllum nodosum extract, 0.01-30% of methyl-tile lactone and 0.01-30% of hypsizygus marmoreus callus culture filtrate;
5-30% of humectant;
0-30% of a skin conditioning agent;
0-10% of a thickening agent;
0.3-5.0% of preservative;
0.01-2% of a chelating agent;
0.01-1% of a solubilizer;
0.01-1.0% of daily essence;
proper amount of pH regulator and deionized water.
2. The emollient water composition comprising liposomes for tightening skin efficacy according to claim 1 wherein: the composition comprises the following components in percentage by weight based on the total weight of the composition:
0.2-25.0% of a firming skin efficacy composition liposome comprising: 0.05-20% of Ascophyllum nodosum extract, 0.05-20% of methyl-tile lactone and 0.05-20% of Craib anisetree callus culture filtrate;
3. the emollient water composition comprising liposomes for tightening skin efficacy according to claim 1 wherein: the firming skin effect composition liposome comprises:
0.05-10% of Ascophyllum nodosum extract, 0.05-10% of methyl-tile lactone and 0.05-10% of hypsizygus marmoreus callus culture filtrate.
4. The emollient water composition comprising liposomes for tightening skin efficacy according to claim 3 wherein: the firming skin effect composition liposome comprises:
0.05-3% of Ascophyllum nodosum extract, 0.05-3% of methyl-tile lactone and 0.05-3% of hypsizygus marmoreus callus culture filtrate.
5. The emollient water composition comprising liposomes for tightening skin efficacy according to any of claims 1 to 4 wherein:
the humectant is selected from one or more of glycerin, propylene glycol, 1, 3-propylene glycol, glycerin acrylate/acrylic acid copolymer, glyceryl polyether-26, hexylene glycol, 1, 2-pentanediol, caprylyl glycol, ethylhexyl glycerin, polyethylene glycol-32, urea, allantoin, PEG/PPG-17/6 copolymer, PPG-28-buthyl polyether-35, bis-PEG-18 methyl ether dimethylsilane, sorbitol, and combinations thereof;
the skin conditioner is selected from one or more of honey extract, arginine, lysine, ornithine, sodium lactate, nicotinamide, yeast extract, Hamamelis virginiana extract, rice chaff extract, ammonium glycyrrhizinate, zinc gluconate, caffeine, and biotin;
the thickening agent is selected from one or a combination of acryloyl dimethyl ammonium taurate/VP copolymer, acryloyl dimethyl ammonium taurate/behenyl alcohol polyether-25 methacrylate cross-linked polymer, sodium polyacrylate, acrylic acid (ester) copolymer sodium, polyacrylate-13, hydroxyethyl acrylate/acryloyl dimethyl sodium taurate copolymer, xanthan gum, hydroxyethyl acrylate/acryloyl dimethyl sodium taurate copolymer, carbomer, acrylic acid (ester)/C10-30 alkanol acrylate cross-linked polymer;
the preservative is selected from one or more of methyl hydroxybenzoate, propyl hydroxybenzoate and phenoxyethanol;
the chelating agent is one or more selected from EDTA-disodium, EDTA-tetrasodium and the composition thereof;
the solubilizer is selected from one or more of PEG-60 hydrogenated castor oil, polysorbate-20 and polysorbate-60;
the pH regulator is selected from one or more of citric acid, sodium citrate, hydroxyethyl piperazine ethane sulfonic acid and a composition thereof.
6. The emollient water composition comprising liposomes for tightening skin efficacy according to claim 1 wherein: the preparation process of the composition liposome with the skin tightening effect comprises the following steps:
1) dissolving lecithin and cholesterol in diethyl ether, and shaking to dissolve until the solution is transparent to obtain an organic phase;
2) removing the ether from the organic phase in the step 1) at constant temperature of 40 ℃ under reduced pressure until a layer of transparent film is formed on the inner side of the bottle wall, and drying for 10min to obtain a dried substance;
3) dissolving Ascophyllum Nodosum extract, mevalonolactone and hypecol callus culture filtrate in phosphate buffer solution with pH of 6.0 to obtain water phase effective components;
4) adding the water phase functional components obtained in the step 3) into the dried substance obtained in the step 2), and performing normal-pressure rotation oscillation hydration and demoulding at the temperature of 35 ℃;
5) and (4) carrying out ultrasonic treatment for 5-20min after complete membrane removal, and filtering to obtain the compact skin effect composition liposome with uniform particle size.
7. The emollient water composition comprising liposomes for tightening skin efficacy according to claim 6 wherein:
the lecithin is soybean lecithin, and the mass ratio of the lecithin to cholesterol is (2-5) to 1;
the mass ratio of the dunaliella salina extract, the mevalonolactone and the hypsizygus marmoreus callus culture filtrate to the lecithin is 1 (1-3): 0.5-1.5): 20-30;
the volume ratio of the water phase to the organic phase is 1 (2-5).
8. The emollient water composition comprising liposomes for tightening skin efficacy according to claim 6 wherein: in the step 5), the particle size of the prepared liposome is 0.1-0.5 μm.
9. The method of preparing a astringent composition containing tight skin efficacy liposomes according to any one of claims 1 to 8, comprising the steps of:
1) adding water, chelating agent, humectant, thickener, part of antiseptic, and pH regulator into water phase pot, stirring and heating to 80-85 deg.C, keeping the temperature and stirring for 20-25 min;
2) boiling cooling water, stirring, cooling to 40-45 deg.C, adding the composition liposome with skin tightening effect, skin conditioner, solubilizer, essence and other antiseptic, adding into emulsifying pot, and stirring for 15-20 min;
3) and continuously stirring and cooling until the temperature is lower than 38 ℃, stopping stirring, and discharging after the detection is qualified.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111126537.9A CN113648259A (en) | 2021-09-26 | 2021-09-26 | Toning lotion composition containing skin-firming liposome and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111126537.9A CN113648259A (en) | 2021-09-26 | 2021-09-26 | Toning lotion composition containing skin-firming liposome and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113648259A true CN113648259A (en) | 2021-11-16 |
Family
ID=78494334
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111126537.9A Pending CN113648259A (en) | 2021-09-26 | 2021-09-26 | Toning lotion composition containing skin-firming liposome and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113648259A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114099410A (en) * | 2021-11-23 | 2022-03-01 | 湖北省麦诗特生物科技有限公司 | Face cream composition with liposome with synergistic anti-aging effect and preparation method thereof |
CN114632045A (en) * | 2022-04-18 | 2022-06-17 | 蔻蔻琪生物科技(杭州)有限公司 | Anti-aging composition, preparation method and application |
CN118141724A (en) * | 2024-03-07 | 2024-06-07 | 广州卡迪莲化妆品科技有限公司 | Sea fennel callus extract, extraction method, cosmetic and sea fennel compound extract |
-
2021
- 2021-09-26 CN CN202111126537.9A patent/CN113648259A/en active Pending
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114099410A (en) * | 2021-11-23 | 2022-03-01 | 湖北省麦诗特生物科技有限公司 | Face cream composition with liposome with synergistic anti-aging effect and preparation method thereof |
CN114099410B (en) * | 2021-11-23 | 2023-06-23 | 湖北省麦诗特生物科技有限公司 | Face cream composition of liposome with synergistic gain and anti-aging effects and preparation method thereof |
CN114632045A (en) * | 2022-04-18 | 2022-06-17 | 蔻蔻琪生物科技(杭州)有限公司 | Anti-aging composition, preparation method and application |
CN114632045B (en) * | 2022-04-18 | 2024-05-31 | 蔻蔻琪生物科技(杭州)有限公司 | Anti-aging composition, preparation method and application |
CN118141724A (en) * | 2024-03-07 | 2024-06-07 | 广州卡迪莲化妆品科技有限公司 | Sea fennel callus extract, extraction method, cosmetic and sea fennel compound extract |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110731924B (en) | Enhanced anti-aging cosmetic compositions | |
CN111297791B (en) | Anti-aging and repairing skin care composition containing symbiotic bacteria combined fermentation product, essence milk and preparation method and application of essence milk | |
CN113648259A (en) | Toning lotion composition containing skin-firming liposome and preparation method thereof | |
KR102265730B1 (en) | cosmetic composition for skin wrinkle improvement and whitening facial skin | |
JP2021020886A (en) | Anti-aging cosmetic composition | |
CN113786362B (en) | Toning lotion composition with effects of relieving balance and protecting skin and preparation method thereof | |
CN108245479B (en) | Facial mask containing bifidobacterium lactis fermented active extract | |
CN107875067A (en) | Skin care composition and use thereof | |
CN113893217B (en) | Face cream composition with freckle-removing effect and preparation method and application thereof | |
JP6007188B2 (en) | Cosmetic composition comprising Honda walla extract, mill extract and wakame extract | |
CN110859796A (en) | Two-step facial mask and preparation method thereof | |
CN113786378B (en) | Toning lotion composition with skin color improving and brightening effects and preparation method thereof | |
CN113876665B (en) | Face cream composition with anti-wrinkle effect and preparation method and application thereof | |
CN111686045A (en) | Skin-tendering facial mask made of plant-derived bacterial cellulose and preparation method of facial mask | |
CN107789316A (en) | A kind of moisturizing antioxidant composition of extract of stem cell containing pot marigold and its application | |
KR20030064059A (en) | Cosmetic composition containing paeonia suffruticosa andrews extract and albizzia julibrissin dura extract having anti-ageing effect | |
CN114588061A (en) | Anti-aging and wrinkle-removing composition, preparation method thereof and skin care product | |
CN113368003A (en) | Composition with overnight muscle repairing effect and preparation method and application thereof | |
CN111904909B (en) | Dandruff removing scalp essence containing rose fermentation liquor and preparation method thereof | |
CN111759762A (en) | Black eye removing composition, essence and preparation method thereof | |
CN113908112B (en) | Face cream composition with effect of improving rough skin and preparation method and application thereof | |
CN107213099B (en) | One kind containing Margarita extract cosmetic material | |
CN112972361B (en) | Composition, preparation method thereof and anti-aging cosmetic | |
CN110478307B (en) | Black eye removal composition, preparation method thereof and cosmetics containing black eye removal composition | |
KR20030055950A (en) | Cosmetic composition containing punica granatum l. extract for anti-aging effect |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20211116 |